Agoracom: Small Cap Investment - Resverlogix Corp. - Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

in response to

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

dlee38

posted on Apr 06, 2022 06:57AM

So if experimental COVID-19 patients taking apabetalone progressed while in the hospital to ICU, the clinical trial states that the treatment will be administered BID with meals. Are meals served in the ICU? Are patients in the ICU coherent enough and are they awake to be served meals? That is why I am puzzled. And again I thank you for your much-appreciated input. :)

Thanks again ... Koo

2 Recommendations

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

dlee38

Apr 06, 2022 08:48AM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients